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Synthesis and antiplasmodial evaluation of novel 
mefloquine-based fumardiamides
The paper is focused on the synthesis and screening of the 
antiplasmodial activity of novel fumardiamides 5–10 with 
the mefloquine pharmacophore and a Michael acceptor 
motif. Multi-step reactions leading to the title compounds 
included two amide bond formations. The first amide bond 
was achieved by the reaction of (E)-ethyl 4-chloro-4-oxobut-
2-enoate (1) and N1-(2,8-bis(trifluoromethyl)quinolin-4-yl)
butane-1,4-diamine (2). The obtained ester 3 was hydro-
lyzed and gave acid 4, which then reacted with the selected 
halogenanilines in the presence of HATU/DIEA and 
formed products 5–10. Title compounds showed marked, 
dose dependent activity in vitro against hepatic stages of 
Plasmodium berghei. IC50 values of the most active com-
pounds 5, 7 and 9 bearing 3-fluoro, 3-chloro and 3-trifluoro-
methyl substituents were 3.04–4.16 µmol L–1, respectively. 
On the other hand, the compounds exerted only weak activity 
against the erythrocytic stages of two P. falciparum strains 
(Pf3D7 and PfDd2) in vitro, with the exception of compound 
5 (IC50 = 2.9 µmol L–1).
Keywords: mefloquine, 2,8-bis(trifluoromethyl)quinoline, 
fumardiamide, halogenaniline, antiplasmodial activity
Mefloquine (MQ) was launched more than 30 years ago for the prophylaxis and treat-
ment of malaria caused by the multidrug-resistant Plasmodium falciparum. Like other quino-
line antimalarials, mefloquine binds to the toxic ferriprotoporphyrin IX and prevents its 
detoxification (1). In addition, the proposed mefloquine targets include ribosomes, phos-
phatidylinositol, volume-regulated anion channels and endocytosis. The main disadvan-
tages of mefloquine include its photochemical instability and cardiovascular, hepatic and/
or neuropsychiatric side effects (2). Also, resistance to mefloquine, connected with in-
creased expression of P-glycoprotein PfMDR1 in the digestive vacuole, has developed (3). 
To overcome mefloquine drawbacks, numerous mefloquine derivatives have been 
prepared, not only as novel antimalarials (4), but also as potential anticancer agents (5, 6). 
MAJA BEUS1,a 
DIANA FONTINHA2,a 
JANA HELD3 
ZRINKA RAJIĆ1 
MIGUEL PRUDÊNCIO2 
BRANKA ZORC1,*
1 University of Zagreb 
Faculty of Pharmacy and Biochemistry 
Department of Medicinal Chemistry 
10 000 Zagreb, Croatia
2 Instituto de Medicina Molecular 
Faculdade de Medicina, Universidade 
de Lisboa, 1649-028 Lisboa, Portugal
3 University of Tübingen 
Institute of Tropical Medicine 
72 074 Tübingen, Germany 
Accepted February 14, 2019 
Published online February 28, 2019
* Correspondence, bzorc@pharma.hr 
a These authors equally contributed to this work.
234
M. Beus et al.: Synthesis and antiplasmodial evaluation of novel mefloquine-based fumardiamides, Acta Pharm. 69 (2019) 233–248.
 
The activity of mefloquine and mefloquine derivatives against Echinococcus multilocularis 
has also been reported (7). More recently, mefloquine has received considerable attention 
as an antimycobacterial agent (8, 9). It is active against Mycobacterium avium and M. tuber-
culosis strains resistant to macrolides, quinolones and rifamycins and shows a synergistic 
effect with ethambutol and moxifloxacin. Antimycobacterial activity of mefloquine de-
rivatives has also been extensively reported (10–12).
In the last ten years, our research group has designed and prepared more than one 
hundred primaquine and chloroquine derivatives with urea, bis-urea, acylsemicarbazide, 
semicarbazide or amide functionalities (13–24). Biological evaluation assays revealed that 
many of these compounds showed potential as antiproliferative, antioxidative, antituber-
cular, antiplasmodial or biofilm eradication agents. Further, we have prepared several 
 SAHAquines based on suberoylanilide hydroxamic acid (SAHA) and primaquine motifs, 
which showed antiplasmodial activity against erythrocytic stages of two P. falciparum 
strains and against P. berghei hepatic stages (22).
In our continued pursuit of novel, biologically active quinoline derivatives, we now 
present the synthesis and evaluation of the antiplasmodial activity of novel fumardi-
amides in which one amide bond was achieved with N1-(2,8-bis(trifluoromethyl)quinolin-
4-yl)butane-1,4-diamine and the other amide was achieved with the corresponding halo-
genaniline. Our compounds can be considered mefloquine derivatives, since they bear the 
same 2,8-bis(trifluoromethyl)quinoline motif as mefloquine. The carbonyl group conju-
gated with the carbon-carbon double bond of the central part of molecules also classifies 
these compounds as Michael acceptors, able to react with biological targets bearing thiol 
groups. We envisaged that combining the mefloquine pharmacophore with Michael acceptor 
and halogenaniline moieties could result in the development of novel antimalarial hits.
EXPERIMENTAL
General
Melting points were determined on an SMP3 apparatus (Barloworld Scientific, UK) in 
open capillaries and are uncorrected. A CEM Discover microwave reactor was used for 
microwave reactions (CEM GmbH, Germany). IR spectra were recorded on a Spectrum 
One (Perkin-Elmer, UK) and UV-Vis spectra on a Lambda 20 double beam spectrophoto-
meter (Perkin-Elmer, UK). NMR 1H and 13C spectra were recorded at 25 °C on an NMR 
Avance 600 spectrometer (Bruker, Germany) at 300.13 or 600.13 and 75.47 or 150.9 MHz for 
1H and 13C nuclei, resp. Chemical shifts (δ) are reported in parts per million (ppm) relative 
to tetramethylsilane in the 1H and the dimethyl sulfoxide (DMSO) residual peak as a refer-
ence in the 13C spectra (39.51 ppm). Coupling constants (J) are reported in Hz. Mass spectra 
were collected on an HPLC-MS/MS instrument (HPLC, Agilent Technologies 1200 Series; 
MS, Agilent Technologies 6410 Triple Quad) using electrospray ionization in positive mode 
(Agilent Technologies, USA). Elemental analyses were performed on a CHNS LECO ana-
lyzer (LECO Corporation, USA). All compounds were routinely checked by TLC with 
Merck silica gel 60F-254 glass plates using dichloromethane/methanol 9.5:0.5, 9:1, 8.5:1.5 
and cyclohexane/ethyl acetate/methanol 1:1:0.5 as solvent systems. Spots were visualized 
by short-wave UV light and iodine vapor. Column chromatography was performed on 
silica gel 0.063–0.200 mm.
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All chemicals and solvents were of analytical grade and were purchased from com-
mercial sources. 4-Chloro-2,8-bis(trifluoromethyl)quinoline, butane-1,4-diamine, (E)-4-ethoxy- 
-4-oxobut-2-enoic acid (mono-ethyl fumarate), 3-fluoroaniline, 4-fluoroaniline, 3-chl oro ani-
line, 4-chloroaniline, 3-trifluoromethylaniline, 4-trifluoromethylaniline and tri ethyl amine 
(TEA) were purchased from Merck GmbH (Germany), and (1-[bis(dimethylamino)
methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid hexafluorophosphate (HATU) and 
N,N-diisopropylethylamine (DIEA) were purchased from Alfa Aesar (USA). Anhydrous sol-
vents were dried and redistilled prior to use.
Syntheses
(E)-ethyl 4-chloro-4-oxobut-2-enoate (Mono-ethyl fumarate chloride) (1). – A solution of 
0.288 g mono-ethyl fumarate (2 mmol) in 7 mL thionyl chloride was kept overnight and 
evaporated under reduced pressure. The residue was triturated several times with anhy-
drous dichloromethane and the solvent was evaporated again. The crude product (0.315 g, 
97 %) was used in further reaction without purification.
N1-[2,8-bis(trifluoromethyl)quinolin-4-yl]butane-1,4-diamine (2). – A mixture of 0.599 g 
(0.02 mol) 4-chloro-2,8-bis(trifluoromethyl)quinoline and 1.763 g 1,4-diaminobutane (0.02 
mol) was stirred under microwave irradiation (300 W) at 95 °C. After 0.5 h, the reaction 
mixture was diluted with dichloromethane, extracted with 5 % NaOH (4 × 40 mL) and 
washed with water (2 × 40 mL). The organic layer was dried over anhydrous sodium sul-
fate, filtrated and evaporated under reduced pressure. White solid 2 was obtained (0.632 g, 
90 %) and used in further reaction without purification.
Ethyl (E)-4-[(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)amino]-4-oxobut-2-eno-
ate (3). – A solution of 0.527 g (1.5 mmol) of amine 2 and 0.152 g (1.5 mmol) TEA in 10 mL of 
anhydrous dichloromethane was added dropwise to chloride 1 dissolved in 10 mL anhy-
drous dichloromethane. The reaction mixture was stirred for 1 h at room temperature and 
extracted 3 times with brine. The organic layer was dried over sodium sulfate, filtered and 
evaporated under reduced pressure. After purification by column chromatography (mo-
bile phase dichloromethane/methanol 9.5:0.5) and crystallization from ether, 0.473 g (66 %) 
of pale yellow solid 3 was obtained.
(E)-4-[(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)amino]-4-oxobut-2-enoic acid 
(4). – A solution of 0.126 g (3 mmol) lithium hydroxide monohydrate in 10 mL water was 
added to a solution of 0.286 g (0.6 mmol) ester 3 in 10 mL methanol. The reaction mixture 
was stirred for 3 h at room temperature. Methanol was evaporated under reduced pressure 
and the aqueous residue was acidified with 10 %-HCl to pH 1. The precipitated product 
was filtered and washed with water until neutral pH was reached. 0.261 g (97 %) of white 
solid 4 was obtained.
Fumardiamides 5–10: General procedure. – A solution of 0.121 g (0.27 mmol) of compound 4, 
0.068 g (0.54 mmol) DIEA and 0.103 g (0.27 mmol) HATU in 1 mL of N,N-dimethylfor-
mamide was stirred at room temperature. After 10 min, 0.297 mmol of the corresponding 
halogenaniline was added. The reaction mixture was stirred 2–24 h at room temperature, 
evaporated under reduced pressure, dissolved in 8 mL ethyl acetate and extracted 3 times 
with water. The organic layer was dried over sodium sulfate, filtered and evaporated un-
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der reduced pressure. The crude products were purified by column chromatography (mo-
bile phase dichloromethane/methanol 9.5:0.5) and crystallized from ether or petroleum 
ether.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(3-fluorophenyl)but-2-en-
ediamide (5). – Reaction of 0.121 g acid 4 and 0.033 g (0.297 mmol) 3-fluoroaniline; after pu-
rification, 0.063 g (43 %) of white solid 5 was obtained.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(4-fluorophenyl)but-2-en-
ediamide (6). – Reaction of 0.121 g acid 4 and 0.033 g (0.297 mmol) 4-fluoroaniline; after pu-
rification, 0.056 g (38 %) of white solid 6 was obtained.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(3-chlorophenyl)but-2-en-
ediamide (7). – Reaction of 0.121 g acid 4 and 0.038 g (0.297 mmol) 3-chloroaniline; after 
purification, 0.072 g (48 %) of white solid 7 was obtained.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(4-chlorophenyl)but-2-en-
ediamide (8). – Reaction of 0.121 g acid 4 and 0.038 g (0.297 mmol) 4-chloroaniline; after 
purification, 0.045 g (31 %) of white solid 8 was obtained.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-[3-(trifluoromethyl)phe-
nyl]but-2-enediamide (9). – Reaction of 0.121 g acid 4 and 0.048 g (0.297 mmol) 3-trifluoro-
methylaniline; after purification, 0.056 g (35 %) of white solid 9 was obtained.
(2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-[4-(trifluoromethyl)phe-
nyl]but-2-enediamide (10). – Reaction of 0.121 g acid 4 and 0.048 g (0.297 mmol) 4-trifluoro-
methylaniline; after purification, 0.037 g (23 %) of white solid 10 was obtained.
Biological evaluation
In vitro activity against P. berghei hepatic stages. – Activity of the synthesized com-
pounds against P. berghei infection in a human hepatoma cell line was assessed employing 
a luminescence-based method, as previously described (25). Briefly, hepatic infection was 
determined by measuring the luminescence intensity of lysates of Huh7 cells, a human 
hepatoma cell line, infected with firefly luciferase-expressing P. berghei sporozoites (Pb-
Luc). Huh7 cells (1.0 × 104 per well) were seeded in 96-well plates on the day before infec-
tion. One hour prior to infection, the medium was replaced by medium containing the 
appropriate drug concentration. Addition of 1.0 × 104 Pb-Luc sporozoites was followed by 
centrifugation at 1800×g for 5 min and the parasite infection load was measured 48 h after 
parasite addition with a bioluminescence assay (Biotium, USA) using a multi-plate reader 
Infinite M200 (Tecan, Switzerland). The effect of different treatments on the viability of 
HuH7 cells was assessed using the CellTiter-Blue assay (Promega, USA) according to the 
manufacturer’s protocol. Nonlinear regression analysis was employed to fit the normalized 
results of the dose-response curves, and IC50 values were determined using GraphPad 
Prism V 5.0.
In vitro drug sensitivity against P. falciparum erythrocytic stages. – In vitro activity of 
tested compounds was evaluated against asexual erythrocytic stages of two P. falciparum 
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laboratory strains, 3D7 (chloroquine sensitive) and Dd2 (chloroquine resistant). Antiplas-
modial activity of fumardiamides 5–10 was assessed by histidine-rich protein 2 (HRP2) 
ELISA, as described before (26, 27). As controls, mefloquine hydrochloride (Sigma, USA) 
and chloroquine diphosphate (Sigma) were used. In brief, 96-well plates were pre-coated 
with the respective compounds or control drugs at a threefold dilution before highly syn-
chronized ring stage parasites were added into complete culture medium at a hematocrit 
of 1.5 % and parasitaemia of 0.05 %. After three days of incubation at 37 °C, 5 % CO2 and 5 % 
oxygen, plates were freeze thawed three times until analyzed by HRP2-ELISA. All com-
pounds were evaluated in duplicate in at least two independent experiments. The 50 % 
inhibitory concentration (IC50) was determined by analyzing the nonlinear regression of 
log concentration-response curves using the drc-package v0.9.0 of R v3.2.2. (28).
Cytotoxicity assay. – Cytotoxicity of novel compounds against the human liver cancer 
cell line Hep G2 (Leibniz Institute DSMZ – German Collection of Microorganisms and Cell 
Cultures, Germany) was evaluated using the neutral red assay (29). In brief, human cells 
were seeded to a 96-well plate in culture medium; on the following day, a serial dilution 
of the respective compound was added. After one day incubation, cytotoxicity was as-
sessed by addition of Neutral Red and subsequent lysis of cells and measuring absorbance 
at l = 570 nm in a plate reader. Inhibitory concentrations were calculated.
RESULTS AND DISCUSSION
Novel fumaric acid diamides 5–10, bearing 2,8-bis(trifluoromethyl)quinoline and 3- or 
4-substituted fluoro-, chloro- or trifluoromethylaniline moieties, were prepared by the 
simple reaction procedures summarized in Scheme 1. The first precursor, (E)-ethyl 4-chlo-
ro-4-oxobut-2-enoate) (1), was prepared from mono-ethyl fumarate and thionyl chloride, 
while the second, N1-(2,8-bis(trifluoromethyl)quinolin-4-yl)butane-1,4-diamine (2), was 
prepared from 4-chloro-2,8-bis(trifluoromethyl)quinoline and 1,4-diaminobutane under 
microwave irradiation. Compounds 1 and 2 reacted under mild reaction conditions to give 
product 3. In this reaction step, TEA was used as a hydrochloride acceptor. Basic hydrolysis 
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of 3 afforded the corresponding acid 4, which reacted with selected halogenanilines and 
formed the title fumardiamides 5–10. HATU was used as a coupling reagent and DIEA as 
a base (known as Hünig′s base). The common precursor 4 enables relatively easy preparation 
of diverse target compounds.  
Purification of compounds was carried out using crystallization methods and/or col-
umn chromatography. Yields for the first two reaction steps were high, but rather low for 
the last one, 23–48 %.
Structures of the new compounds were confirmed by 1H, 13C NMR and IR spectra and 
additionally by elemental analysis. Chemical shifts, multiplicities and coupling constants 
confirmed the proposed structures. Analytical and spectral data of the target compounds 
5–10 and their precursors are given in Table I. Atom numbering used in the current study 
is indicated in Fig. 1.
Fig. 1. Atom numbering of compounds 5–10.
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In 1H NMR spectra, NH-1’ signals were visible as sharp singlets between d 10.78 and 
10.45, NH-5 signals as triplets at 8.55–8.47 ppm, while NH-10 signals were mixed with aro-
matic H-atoms. All NH signals were D2O exchangeable. In 
13C NMR spectra, the CF3 group 
at position 21 had a signal between d 129.41 and 116.72 ppm and between 127.11 and 116.23 
ppm at position C-20. Two additional CF3 groups in compounds 9 and 10 appeared at 
similar ppm values (d 130.08-129.00 and 128.72-127.75 ppm). All CF3 signals were quartets 
with high coupling constants (277.70-272.73 Hz). The carbon atoms bearing trifluoromethyl 
groups, i.e., atoms C-15, C-13 and C-4’ or C-5’, in compounds 9 and 10 showed quartets with 
markedly lower coupling constants (33.22-27.30 Hz), while fluorosubstituted carbons 4’ 
and 5’ in compounds 5 and 6 appeared as doublets at d 163.71-160.51 and 159.03-157.44 ppm. 
Signals of the analogous chlorosubstituted carbons in compounds 7 and 8 were down-
shifted at d 133.12 and 127.38 ppm. In all compounds, carbonyl C-atoms C-1 and C-4 ap-
peared between d 163.41 and 162.16 ppm. IR spectra revealed the presence of two sets of 
amide I and amide II signals between 1652 and 1512 cm–1. 
Chemical structure of the new compounds was also supported by mass spectrometry 
analysis. Molecular ion peaks corresponding to the expected molecular masses were ob-
tained for all compounds. m/z data and the expected relative molecular masses are given 
in Table I, while all IR, NMR and mass spectra are available as Supplementary material.
We have also applied Chemicalize.org (30) and SwissADME programs (31) to compute 
physicochemical descriptors as well as to predict ADME parameters, pharmacokinetic 
properties, drug-like nature and medicinal chemistry friendliness of our fumardiamides. 
A set of physicochemical parameters, i.e., number of atoms, molecular mass (MW), parti-
tion coefficient (log P), number of H-bond donors (HBD), number of H-bond acceptors 
(HBA), molar refractivity (MR) and topological polar surface area (TPSA) are given in Table 
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II (30). All compounds showed minimum aberration in molecular masses and log P, while 
the other four parameters are fully in agreement with Lipinski’s and Gelovani’s rules. 
SwissADME bioavailability radars for the most active compounds 5, 7 and 9 are given in 
Fig. 2 (31). Radars enable a first glance at the drug-likeness of the molecules. The pink area 
represents the optimal range for each property: lipophilicity (LIPO) (XLOGP3 between 
−0.7 and +5.0), molecular mass (SIZE) (between 150 and 500 g mol–1), polarity (POLAR) 
(TPSA between 20 and 130 Å2), solubility (INSOLU) (log S not higher than 6), saturation 
(INSATU) (fraction of carbons in the sp3 hybridization not less than 0.25), and flexibility 
(FLEX) (no more than 9 rotatable bonds). All three compounds are too flexible and are thus 
predicted as not orally bioavailable.
Biological evaluation
To evaluate the antiplasmodial potential of the title fumardiamides, in vitro assays 
against two strains of P. falciparum erythrocytic stages, Pf3D7 and PfDd2, and against P. 
berghei hepatic stages were performed. Our results showed that only compound 5 dis-
played marked activity against P. falciparum blood stages, with an IC50 of 2.9 µmol L–1 
(Table III). On the other hand, all the compounds evaluated in this work showed promising 
antiplasmodial in vitro activity against P. berghei. Fumardiamides were tested at 1 and 10 
µmol L–1, and DMSO was used as a negative control (Fig. 3). The most active compounds 
(5, 7 and 9) had very similar IC50 values, ranging between 3.04 and 4.16 µmol L–1 (Fig. 4), 
indicating that the type of halogen (fluorine or chlorine) had no influence on the com-
pound activity against the parasite’s hepatic stages, but had a slight impact on cytotoxicity. 
Among the three most active compounds, 3-fluoro derivative 5 showed the best activity/
toxicity ratio (Table IV). Replacement of the halogen atom with CF3 group caused slight 
perturbations of electron density of the aromatic scaffold, but this change also had a neg-
ligible effect on the activity. Comparison of the structural isomers 5 and 6, 7 and 8, and 9 
and 10 revealed that meta-substituted derivatives were slightly more active than the analo-
gous para-substituted derivatives. Cytotoxicity studies performed on the human liver can-
cer cell line (HepG2) cells revealed low cytotoxicity of fumardiamides 5–10. These studies 
Table II. Calculated physiochemical descriptors of diamides 5–10 (30)
Cmpd.
Molecular 
formula
Number 
of atoms
Mr log P HBD HBA
MR 
(cm3 mol–1)
TPSA 
(Å2)
5 C25H21F7N4O2 59 542.458 5.10 3 4 129.11 83.12
6 C25H21F7N4O2 59 542.458 5.10 3 4 129.11 83.12
7 C25H21ClF6N4O2 59 558.910 5.57 3 4 133.70 83.12
8 C25H21ClF6N4O2 59 558.910 5.57 3 4 133.70 83.12
9 C26H21F9N4O2 62 592.466 5.84 3 4 134.87 83.12
10 C26H21F9N4O2 62 592.466 5.84 3 4 134.87 83.12
Mr – relative molecular mass; log P  – partition coefficient; HBD – H-bond donor; HBA – H-bond acceptor; MR – 
molecular refractivity; TPSA – topological polar surface area
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log P = 5.18
MW = 542.45 g/mol
TPSA = 83.12 Å
log S = –5.92
Fraction Csp3 = 0.24
Rotable bonds = 13
5
N
N
H
H
N
N
H
O
O
F
F3C
F3C
log P = 5.71
MW = 558.90 g/mol
TPSA = 83.12Å
log S = – 6.36
Fraction Csp3 = 0.24
Rotable bonds = 13
7
N
N
H
H
N
N
H
O
O
Cl
F3C
F3C
log P = 5.97
MW = 592.46 g/mol
TPSA = 83.12Å
log S = – 6.64
Fraction Csp3 = 0.27
Rotable bonds = 14
9
N
N
H
H
N
N
H
O
O
CF3
F3C
F3C
Fig. 2. Bioavailability radars for the most active compounds 5, 7 and 9. The pink area represents the 
optimal range for each property (lipophilicity, size, polarity, solubility, saturation and flexibility).
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are only preliminary. To get a better insight into the toxicity of prepared compounds, more 
cell lines should be tested and additional cytotoxicity tests should be performed.
Fig. 3. Activity of compounds 5–10 against P. berghei liver-stages at 1 and 10 µmol L–1 concentrations. 
Anti-infective activity (infection scale, bars) is shown. Results represent mean ± SD, n = 1.
Fig. 4. IC50 of selected MQ-derivatives against P. berghei hepatic stages. IC50 = 4.16 (5), 3.64 (7) and 3.04 
(9) µmol L–1. Results represent mean ± SD, n = 1.
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Table III. IC50 values of compounds 5–10 against the erythrocytic stage of two P. falciparum strains
Cmpd. Chemical structure
IC50 (µmol L–1)
Pf3D7 PfDd2
5 N
N
H
H
N
N
H
O
O
F
F3C
F3C
2.9 15.2
6 N
N
H
H
N
N
H
O
O
F3C
F3C
F
> 13.0 > 13.0
7 N
N
H
H
N
N
H
O
O
Cl
F3C
F3C
18.5 > 13.0
8 N
N
H
H
N
N
H
O
O
F3C
F3C
Cl
> 13.0 > 13.0
9 N
N
H
H
N
N
H
O
O
CF3
F3C
F3C
> 13.0 16.9
10 N
N
H
H
N
N
H
O
O
F3C
F3C
CF3
> 13.0 > 13.0
Mefloquine 6.5 × 10–3 6.6 × 10–3
Chloroquine 3.7 × 10–3 0.2
Primaquine 2.0 1.8
Table IV. Cytotoxicity screening of compounds 5–10 towards the human liver cancer cell line (Hep G2)
Cmpd.
IC50 
(µmol L–1)
5 64.1 ± 54.2
6 > 100
7 10.0 ± 3.6
8 > 100
9 13.0 ± 2.6
10 > 100
Primaquine 148.0 ± 3.5
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CONCLUSIONS
Novel fumardiamides 5–10 with the mefloquine pharmacophore and Michael accep-
tor motif were designed and synthesized through multi-step reactions. Three compounds, 
namely (2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(3-fluorophenyl)
but-2-enediamide (5), (2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]amino}butyl)-N-(3-
chlorophenyl)but-2-enediamide (7) and (2E)-N’-(4-{[2,8-bis(trifluoromethyl)quinolin-4-yl]
amino}butyl)-N-[3-(trifluoromethyl)phenyl]but-2-enediamide (9), provided fairly promis-
ing results in the in vitro bioassay against P. berghei liver stages, while compound 5 was also 
active against the blood stages of two P. falciparum strains. These compounds could serve 
as starting points for further optimization and development of more potent agents.
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